Skip to main content
  • Home
  •  Elevating Understanding and Management of Hypertriglyceridemia: From Risk Factor to Novel Therapeutic Target

Elevating Understanding and Management of Hypertriglyceridemia: From Risk Factor to Novel Therapeutic Target

  • Prevention

Available Credit:

  • 1.25 AMA PRA Credit

Course Published On:

Course Expiry Date:

Elevating Understanding and Management of Hypertriglyceridemia
No ratings


This microlearning series entitled 'Elevating Understanding and Management of Hypertriglyceridemia: From Risk Factor to Novel Therapeutic Target' aims to provide guidance on how to identify, manage, and treat hypertriglyceridemia (HTG) in your patients and improving patient outcomes.


The programme is aimed to improve understanding of HTG as a risk factor for acute and chronic illness, address challenges of diagnosing and treating elevated TG levels and review latest data for emerging therapies. 


Guided by the expertise of renowned leaders in the field, including Dr Christie Ballantyne (Baylor College of Medicine, Texas, US) as programme chair, who is accompanied by Dr Robert Eckel (University of Colorado, Colorado, US), Prof Ioanna Gouni-Berthold (University of Cologne, Cologne, DE) and Dr Nicholas Marston (Brigham and Women’s Hospital, Boston, US), this series comprises five succinct sessions designed to revolutionise your approach to HTG management.

Support Statement

This programme is supported by an unrestricted educational grant from Ionis Pharmaceuticals.

Joint Accreditation and Credit Designation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education through the joint providership of i3 Health and Radcliffe Medical Education. In support of improving patient care, i3 Health is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.


i3 Health designates this enduring material for a maximum of 1.25 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Instruction to Participants

There is no fee for taking part in this online learning activity. Activities are designed to be completed within 75 minutes and must be completed by the registered user. Physicians should only claim credits for time spent on the activity. To successfully earn credit, participants must complete the activity in full in the indicated time frame.

To complete the course and claim certification participants must:

  • Read the course outline information supplied and complete pre-test questions prior to starting the activity.
  • Users must read and study the activity in its entirety before completing the post-test questions.
  • Your results will be automatically saved and if a pass score is achieved (where applicable), you may be eligible to claim credit for the activity and receive a certificate of completion.


The information provided at this CME/NCPD/CPE activity is for continuing education purposes only and is not meant to substitute for the independent medical/clinical judgment of a healthcare provider relative to diagnostic and treatment options of a specific patient’s medical condition.


i3 Health requires CME/NCPD/CPE faculty (speakers) to disclose to attendees when products or procedures being discussed are off-label, unlabelled, experimental, and/or investigational (not FDA approved), as well as any limitations on the information that is presented, such as data that are preliminary or that represent ongoing research, interim analyses, and/or unsupported opinion. Faculty may discuss information about pharmaceutical agents that is outside of U.S. Food and Drug Administration approved labelling. This information is intended solely for continuing medical education and is not intended to promote off-label use of these medications. If you have questions, contact the medical affairs department of the manufacturer for the most recent prescribing information.


i3 Health and Radcliffe Medical Education planners, reviewers, and managers have nothing to disclosure.


i3 Health and Radcliffe have mitigated all relevant financial relationships.

Technical/Credit Queries

Technical queries about this activity should be directed to Questions regarding activity credit should be directed to

Target Audience

This programme is intended to educate:

  • Cardiologists
  • Lipidologists
  • Other Allied HCPs

Learning Objectives

Upon participation in this programme physicians should be able to:

  • Understand HTG as a risk factor for acute and chronic illness
  • Describe current guideline directed management of HTG
  • Recognise the gaps and challenges present in current guideline directed management of HTG
  • Recall emerging trial data for novel pharmacological targets
  • Use guidelines, trial data & expert opinion to develop individualised treatment strategies for high-risk patients
Register now Log in





Part 1 Hypertriglyceridemia: A Risk Factor for Acute & Chronic Illness 12 mins Robert Eckel (Colorado, US)
Part 2 Current Guideline-Directed Approach to Hypertriglyceridemia 18 mins Ioanna Gouni-Berthold (Cologne, DE)
Part 3 Gaps & Challenges within Current Approach 12 mins Christie Ballantyne (Texas, US)
Part 4 Novel Pharmacological Management of HTG 13 mins Nicholas Marston (Boston, US)
Part 5 Discussion: Optimal Approach to HTG Diagnosis & Management 17 mins Christie Ballantyne (Texas, US) Robert Eckel (Colorado, US) Ioanna Gouni-Berthold (Cologne, DE) Nicholas Marston (Boston, US)
Part 1.

Hypertriglyceridemia: A Risk Factor for Acute & Chronic Illness

Duration: 12 mins

Speakers: Robert Eckel (Colorado, US)

Part 2.

Current Guideline-Directed Approach to Hypertriglyceridemia

Duration: 18 mins

Speakers: Ioanna Gouni-Berthold (Cologne, DE)

Part 3.

Gaps & Challenges within Current Approach

Duration: 12 mins

Speakers: Christie Ballantyne (Texas, US)

Part 4.

Novel Pharmacological Management of HTG

Duration: 13 mins

Speakers: Nicholas Marston (Boston, US)

Part 5.


Christie Ballantyne

Christie Ballantyne

Baylor College of Medicine, Houston, Texas

Dr Christie Ballantyne is the Chief of Cardiovascular Research, Director of the Center for Cardiometabolic Disease Prevention, and Professor of Medicine at Baylor College of Medicine in Texas, US.

View full profile


Robert Eckel

Robert Eckel

University of Colorado Anschutz Medical Campus, Aurora, CO, US

Dr Robert Eckel is Professor of Medicine in the Division of Endocrinology, Metabolism and Diabetes at the University of Colorado Anschutz Medical Campus, Colorado, US. 

View full profile
Ioanna Gouni-Berthold

Ioanna Gouni-Berthold

University of Cologne, Cologne, DE

Prof Ioanna Gouni-Berthold is Professor of Internal Medicine and Head of the Lipid Research Clinic at the Policlinic for Endocrinology, Diabetes and Preventive Medicine at the University of Cologne in Germany.

View full profile
Nicholas Marston

Nicholas Marston

Brigham and Women's Hospital, Boston, US

Dr  Nicholas Marston is a Cardiologist at the Preventive Cardiology Section and Cardiovascular Genetics Section at Brigham and Women's Hospital in Boston, US. 


View full profile
1.25 AMA PRA Credit

Related Courses

Hyperkalaemia in Cardiorenal Disease – A Case Based Discussion
  • Not accredited

Learning objectives

  • Explain the relationship between sub-optimal RAASi therapy and poor cardio-renal outcomes
  • Identify patients who would benefit from anti-hyperkalaemia medications
  • Select appropriate anti-hyperkalaemia treatments across a range of patient profiles
  • Adopt anti-hyperkalaemia medications as an approach to prolong optimal RAASi therapy
  • Summarise current guideline recommendations on the use of potassium binding agents
See more
Examining a Complex Heart Failure Case
  • 1.00 EBAC

Learning objectives

  • Identify individuals likely to have HFpEF from initial presentation
  • Refer suspected individuals for specialist assessment
  • Initiate GDMT for HF as soon as patients are stable 
  • Initiate GDMT in HF regardless of EF and phenotype
  • Initiate shared decision-making on complex HF patients with other members of the multidisciplinary team including cardiologists, GPs, nephrologists and diabetologists
See more
CVD and Type 2 Diabetes: Navigating Therapeutic Boundaries in GLP-1 RA Use
  • 2.00 EBAC

Learning objectives

  • Describe the burden of ASCVD in type 2 diabetes
  • Assign risk of future CV events to individuals with type 2 diabetes
  • Identify appropriate patients for GLP-1 RA therapy based on clinical trial outcome data to reduce ASCVD risk
  • Recall trial data of anti-diabetes medications that reduce ASCVD risk
  • Recall the pleiotropic effects of GLP-1 RAs and how these may impact CV outcomes
  • Describe how early adoption of anti-diabetes therapies with proven CV benefit can positively influence QOL
  • Adopt anti-diabetic therapies with proven ASCVD benefit
See more
Obstructive Hypertrophic Cardiomyopathy: Getting It Right First Time
  • 1.00 EBAC

Learning objectives

  • Recall the general approach to diagnosis and stratification of HCM according to the latest guidelines and expert opinion
  • Apply advanced echocardiographic methodologies to equivocal HCM diagnoses
  • Select appropriate imaging modalities to facilitate accurate risk stratification
  • Stratify patients based on specific risk features and disease severity
  • Choose suitable treatment modalities for patients based on specific disease features and severity
See more